Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The first-in-man study of CCS1477 for the treatment of Castrate resistant prostate cancer

Next Previous
Trial Profile

The first-in-man study of CCS1477 for the treatment of Castrate resistant prostate cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; Enzalutamide (Primary) ; Inobrodib (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 25 Jun 2018 According to a CellCentric media release, this clinical trial has been initiated following regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA).
  • 25 Jun 2018 According to a CellCentric media release, status changed from planning to recruiting.
  • 25 Jun 2018 According to a CellCentric media release, this study is being led by Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top